Summary: A pilot randomized, controlled clinical trial provides the first targeted clinical evidence that immunotherapy may offer a new treatment avenue for people with treatment-resistant depression. The study tested whether tocilizumab, an anti-inflammatory drug commonly used for autoimmune conditions such as rheumatoid arthritis, can relieve depressive symptoms by blocking a specific inflammatory pathway.
By selecting a small group of patients who showed persistent, low-grade systemic inflammation, researchers bypassed the conventional focus on brain neurotransmitters and demonstrated that reducing peripheral inflammation can lead to meaningful clinical improvements and remission for some patients.
Key Facts
- The Serotonin Bottleneck: Standard antidepressants act on brain monoamines such as serotonin, norepinephrine, and dopamine, but roughly one in three people with depression do not respond to these treatments.
- The Inflammatory Undercurrent: About 33% of people with depression show inflammatory markers in their blood, suggesting that an overactive peripheral immune system may drive symptoms for a subset of patients.
- Targeting the IL-6 Pathway: Genetic studies using Mendelian randomization and longitudinal cohort data point to interleukin 6 (IL-6) — a central inflammatory cytokine — as a causal contributor to depression rather than a mere correlate.
- Notable Remission Rates: In this proof-of-concept trial, 54% of participants treated with tocilizumab reached clinical remission versus 31% in the placebo group.
- Number Needed to Treat (NNT): The trial produced an NNT of 5 for the tocilizumab group, indicating that treating five similar patients would yield one additional remission compared with placebo. This compares favorably with first-line selective serotonin reuptake inhibitors (SSRIs), which have an NNT around 7.
- Precision Medicine Approach: The trial is notable for targeting the IL-6 receptor (IL-6R) and for using biological screening to select patients most likely to benefit from immunotherapy, illustrating a precision psychiatry model.
Source: University of Bristol
Immunotherapy as a potential option for difficult-to-treat depression
A University of Bristol-led pilot randomized controlled trial, published in JAMA Psychiatry on 20 May, explored whether tocilizumab could improve depressive symptoms in people with moderate-to-severe depression who had not responded to standard antidepressants. Tocilizumab is an IL-6 receptor antagonist already licensed for inflammatory conditions like rheumatoid arthritis.
Although the trial enrolled only 30 people, it delivers early evidence that blocking the IL-6 inflammatory pathway may reduce depressive symptoms, fatigue, and anxiety, while improving overall quality of life, compared with a saline placebo.
Typical antidepressants focus on brain chemistry, but many patients do not benefit from that approach. Emerging research indicates that peripheral inflammation contributes to depression in a substantial subset of patients. Elevated inflammatory proteins, including IL-6, have been associated with depressive symptoms, and genetic and cohort studies suggest a causal role for this cytokine.
The trial specifically recruited adults with moderate-to-severe ICD-10 depression who had poor responses to prior antidepressants, exhibited low-grade systemic inflammation (confirmed by two separate high-sensitivity C-reactive protein tests), and showed somatic depressive symptoms. Participants were randomized to a single intravenous infusion of tocilizumab (8 mg/kg, up to 800 mg) or normal saline and were assessed over four weeks.
As expected for a small proof-of-concept study, few findings reached formal statistical significance. Nonetheless, the tocilizumab group displayed a consistent pattern of greater improvement over time across multiple outcomes — somatic symptoms, overall depression severity, fatigue, psychological symptoms, state anxiety, and quality of life — with the largest differences observed at day 28. At final follow-up, remission rates favored tocilizumab (53.9% vs 31.3%), yielding an NNT of 5; response rates also favored tocilizumab (46.2% vs 18.8%; NNT = 4).
Baseline hs-CRP tracked clinical improvement better than IL-6 levels in this sample, suggesting that hs-CRP may be a more practical biomarker for selecting patients likely to benefit from anti–IL-6 immunotherapy. Tocilizumab was well tolerated with no serious adverse events or study withdrawals reported.
Professor Golam Khandakar, the study’s senior author, noted that this trial is an important step toward new treatments for difficult-to-treat depression and represents one of the first randomized tests of immunotherapy with an IL-6R target combined with targeted patient selection.
Dr Éimear Foley, lead author, emphasized the potential for more personalized depression care: matching treatments to biological signatures could help provide the right therapy for the right patient at the right time.
A larger phase III randomized controlled trial is the logical next step to confirm efficacy and enable clinicians to consider immunotherapy as a prescription option for depression when appropriate.
Funding: This double-blind, proof-of-concept trial involved 30 participants recruited via the University of Cambridge and the Cambridgeshire and Peterborough NHS Foundation Trust, with four weeks of follow-up. The research was funded by Wellcome, with additional support from NIHR Biomedical Research Centres in Bristol and Cambridge and the BMA Foundation J Moulton grant.
Key Questions Answered:
A: While traditional psychiatry has focused on neurotransmitter imbalances, growing evidence shows that peripheral inflammation can influence brain function. High levels of IL-6 and related inflammatory signals circulate throughout the body and can alter neural circuits tied to mood. By blocking IL-6 signaling with tocilizumab, peripheral inflammation is reduced, which can in turn ease inflammation-driven changes in the brain and relieve depressive symptoms in patients whose illness is driven by immune activation.
A: Small pilot trials are typically underpowered to deliver definitive statistical significance. The milestone here is the clear directional signal across multiple clinically meaningful outcomes, the higher remission and response rates, and the demonstration that a targeted, biomarker-guided approach can produce substantial benefit. These findings justify a larger, definitive phase III trial.
A: The trial’s strength lies in its precision design: participants were selected based on both treatment resistance and replicated evidence of low-grade inflammation. Rather than treating all patients indiscriminately, the investigators matched the therapeutic mechanism to a biological signature, illustrating a precision psychiatry model that could improve treatment targeting and outcomes.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this immunotherapy and psychopharmacology research news
Author: Joanne Fryer
Source: University of Bristol
Contact: Joanne Fryer – University of Bristol
Image: Image credited to Neuroscience News
Original Research: “Interleukin 6 as a treatment target for depression: a proof-of-concept randomized clinical trial” by Éimear M. Foley et al., JAMA Psychiatry. DOI: 10.1001/jamapsychiatry.2026.1053
Abstract
Interleukin 6 as a treatment target for depression: a proof-of-concept randomized clinical trial
Importance Interleukin 6 (IL-6) is a central inflammatory cytokine with growing evidence implicating it in the pathogenesis of depression, yet randomized trials testing IL-6 inhibition for depression remain limited.
Objective To estimate likely treatment-sensitive outcomes and effect sizes for systemic IL-6 inhibition in patients with difficult-to-treat depression and to inform design of larger efficacy trials.
Design, Setting, and Participants This 4-week, double-blind, parallel-arm, placebo-controlled randomized trial enrolled adults with moderate-to-severe ICD-10 depression, poor antidepressant response, low-grade systemic inflammation (hs-CRP ≥0.3 mg/dL on two tests), and somatic depressive symptoms. Participants were assessed at baseline and at days 7, 14, and 28.
Intervention A single intravenous infusion of the IL-6 receptor antagonist tocilizumab (8 mg/kg, max 800 mg) or normal saline.
Main Outcomes and Measures The primary outcome was somatic depressive symptoms at day 14; secondary outcome was total depression severity. Exploratory outcomes included fatigue, anxiety, anhedonia, quality of life, and cognition, measured with validated instruments and interpreted against clinically meaningful thresholds.
Results Thirty participants (mean age 41.1 years; 80% female) were randomized (14 to tocilizumab, 16 to placebo); 29 completed follow-up. No outcome reached formal statistical significance, as expected for a small trial. Nevertheless, tocilizumab showed a consistent, stepwise pattern of greater improvement across multiple outcomes, with the largest differences at day 28. At final follow-up, remission favored tocilizumab (53.9% vs 31.3%; NNT = 5) and response rates also favored tocilizumab (46.2% vs 18.8%; NNT = 4). Baseline hs-CRP, but not IL-6 level, correlated with clinical improvement. Tocilizumab was well tolerated with no serious adverse events.
Conclusions and Relevance These findings identify outcomes, effect sizes, and patient-selection methods useful for designing large-scale trials of systemic IL-6 inhibition in difficult-to-treat depression and support conducting a phase III efficacy trial.
Trial Registration ISRCTN16942542